美国不同种族和族裔的骨质疏松症流行病学、诊断与管理
综述指出美国不同种族和族裔在骨质疏松症流行病学、诊断和管理上存在差异。黑人和亚洲女性的骨折率比白人女性低约40%至50%,西班牙裔女性骨折率一般低于白人女性但差异程度不确定。美国FRAX纳入种族因素,使亚洲、黑人和西班牙裔人群的计算风险降低0.43至0.64。抗骨吸收治疗中亚洲患者非典型股骨骨折至少常见6倍。存在筛查率、治疗率较低和骨折后结局较差的差异。
要点
- 黑人和亚洲女性骨折率比白人女性低约40%至50%。
- 美国FRAX纳入种族,使亚洲、黑人和西班牙裔风险降低0.43至0.64。
- 抗骨吸收治疗中亚洲患者非典型股骨骨折至少常见6倍。
核心结论
- 骨质疏松症的流行病学、诊断和管理受种族和族裔影响,存在筛查率、治疗率和骨折后结局的差异。
- 倡导对所有种族中高风险患者采取更积极的筛查、治疗和纳入研究的方法。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 黑人和亚洲女性骨折率比白人女性低约40%至50%。
- 西班牙裔女性骨折率一般低于白人女性,但差异程度不确定。
- 男性研究较少。
- 骨密度和结构的显著差异贡献了骨折率的差异。
- 非典型股骨骨折在抗骨吸收治疗的亚洲患者中至少常见6倍。
关键数值与推荐
- 骨质疏松症诊断可依据既往脆性骨折、骨密度T值小于或等于-2.5或FRAX计算的高骨折评分。
- 美国FRAX纳入种族,使亚洲、黑人和西班牙裔人群的计算风险降低0.43至0.64。
- 抗骨吸收治疗疗效未报告主要种族差异。
临床怎么用
- 将种族因素纳入骨质疏松症治疗算法。
- 对所有种族中骨折后结局较差风险的患者采取更积极的筛查和治疗。
- 关注亚洲患者抗骨吸收治疗中非典型股骨骨折风险。
局限性
- 男性研究较少。
- 西班牙裔女性骨折率差异程度不确定。
- 并非所有试验报告了按种族的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporosis is a systemic skeletal disease of reduced bone strength that leads to an increased risk of fragility fracture. Osteoporosis epidemiology, diagnosis, and management all are influenced by race and ethnicity. Studies have found approximately 40% to 50% lower fracture rates in Black and Asian as compared to White women. Hispanic women have generally been shown to have lower fracture rates than White women, but the magnitude of difference is uncertain. Studies in men are fewer. Substantial differences in bone density and structure contribute to these differences in fracture rates. The diagnosis of osteoporosis can be made by prior fragility fracture, bone mineral density T-score of less than or equal to -2.5, or by high calculated fracture score using the Fracture Risk Assessment Tool (FRAX). FRAX in the United States incorporates race, which has the effect of lowering calculated risk for Asian, Black, and Hispanic people by 0.43 to 0.64. In regard to pharmacotherapy, while not all trials have reported efficacy by race, there are not major known differences in osteoporosis treatment efficacy by race. Atypical femur fractures, rare subtrochanteric or diaphyseal fractures, are at least 6 times more common in Asian patients with antiresorptive therapies. Finally, there are important disparities in osteoporosis by race, including lower screening rates, lower treatment rates, and worse outcomes after fracture. Our review examines these racial differences in osteoporosis and provides an approach to incorporate race into the osteoporosis treatment algorithm. We advocate for a more aggressive approach to screening, treatment, and inclusion in research for patients of all races at risk of poor outcomes, acknowledging racial disparities in postfracture outcomes.
引用
- Dickens LT, Abe CM, Connors M, et al. Osteoporosis Epidemiology, Diagnosis, and Management Across Race and Ethnicity in the United States. J Clin Endocrinol Metab. 2025. PMID: 40820822. doi:10.1210/clinem/dgaf466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。